ArticleXenotransplantation
Quantitative Proteomic Analysis of Cardiac Xenograft Failure in a Pig-to-Non-Human Primate Model Identifies NF-κB as a Critical Immunomodulatory Target.
Article in Xenotransplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Xenotransplantation Literature Update: January-June 2025.XenotransplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionShortage of donor organs is one of the greatest challenges of cardiac transplantation. Xenotransplantation is a potential way to solve the contradiction of imbalance and pigs are considered ideal donor sources. However, xenotransplantation still faces the problem of immune rejection at present. In order to further understand the molecular picture of immune rejection after xenotransplantation, and develop immunosuppressive agents to further overcome rejection, we conducted a proteomic analysis of a heterotopic pig-to-non-human primate (NHP) animal model.
methodsWe constructed a heterotopic NHP animal model using wild-type (WT) and alpha-1,3-galactosyltransferase gene knockout (GTKO) porcine hearts as donors. Based on quantitative proteomics analysis, we investigated the changes of protein after CXTx in three groups: Group I: WT donor heart, Group II: GTKO donor heart without immunosuppression, and Group III: GTKO donor heart with immunosuppression. Finally, we assessed the efficacy of the target using a heterotopic heart transplantation model from SD rats to Balb/c mice.
resultsA total of 2425 proteins were identified in the donor heart tissues and approximately 15% of proteins were significantly changed after CXTx, most of them had increased expression. The results of proteomic analysis demonstrated that chronic hypoxia injury induced by microvascular thrombosis may play an important role during cardiac xenograft failure, confirmed by histopathological results. Remarkably, we showed some novel targets especially increased expression of pentraxin 3, MVP, and HSP90AB1 that cannot be suppressed in the present gene editing and immunosuppressive interventions. Because NF-κB is a common downstream regulator of these three proteins, we hypothesize that it may be crucial to the occurrence of xenograft failure and considered as a potential therapeutic target. Using the SD Rat-Balb/C Mouse CXTx model and inhibiting NF-κB with BAY 11-7082, we found that NF-κB targeting prolonged graft survival from 5 to 8 days and reduced myocardial inflammation.
conclusionsIn summary, the proteomic analysis could help us to solve the mystery of cardiac xenograft failure, confirm the key pathways, and reveal a clear vision of future interventions. NF-κB inhibition effectively decreased immune cell infiltration and antibody deposition in myocardial tissue, suggesting its potential as a therapeutic strategy to enhance graft survival and reduce inflammation in cardiac xenotransplantation (CXTx).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.